CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM078520
035-os BibID:(PMID)31002856 (WoS)000466942100010 (Scopus)85064701689
Első szerző:Keserű Judit (molekuláris genetikus)
Cím:Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer / Keserű J. S., Soltész B., Lukács J., Márton É., Szilágyi-Bónizs M., Penyige A., Póka R., Nagy B.
Dátum:2019
ISSN:0168-1656
Megjegyzések:Ovarian tumor is one of the leading causes of cancer among women. Patients are diagnosed at an advanced stage, usually. There is a need for new specific and sensitive biomarkers. Mitochondrial DNA copy number change was observed in various cancers. Our aim was to detect mitochondrial DNA copy number in whole blood (wb-mtDNA) and in plasma (cell-free and exosome encapsulated mtDNA) in patients with serous epithelial ovarian tumor. DNA was isolated from EDTA blood and plasma obtained from 24 patients and 24 healthy controls. Exosomes were isolated from cell-free plasma, and exosome encapsulated DNA (exoDNA) was extracted. Quantitative-real-time PCR was performed with Human Mitochondrial DNA (mtDNA) Monitoring Primer Set. Kruskall?Wallis and Mann?Whitney U test were used for data analysis. Wb-mtDNA copy number was significantly different among healthy controls and patients in multiple comparison (p?=?0.0090 considering FIGO stage independently, and p?=?0.0048 considering early- and late-stage cancers). There was a significant decrease among early-stage, all advanced stage and all cancer patients (FIGO I: 32.5?±?8.3, p?=?0.0061; FIGO III?+?IV: 37.2?±?13.7 p?=?0.0139; FIGO I?+?III?+?IV: 35.6?±?12.2, p?=?0.0017) or FIGO III patients alone (32.8?±?5.6, p?=?0.00089) compared to healthy controls. We found significant increase in copy number in exosomal mtDNA in cancer patients (236.0?±?499.0, p?=?0.0155), advanced-stage cancer patients (333.0?±?575.0, p?=?0.0095), of FIGO III (362.0?±?609.2, p?=?0.0494), and FIGO IV (304.0?±?585.0, p?=?0.0393) patients alone but not in samples of FIGO I patients (10.0?±?3.5, p?=?0.3907). In multiple comparison the increase was significant considering early- and late-stage cancers (p?=?0.0253). Cell-free mtDNA copy numbers were not increased significantly. We found the highest copy number of mtDNA in exosomes, followed by plasma and peripheral blood in late-stage cancer patients. We observed significant difference in wb-mtDNA copy number between healthy controls and both early- and late-stage cancer patients.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Cell-free mtDNA
Exosomal mtDNA
Mitochondrial DNA
Serous ovarian cancer
Megjelenés:Journal of Biotechnology. - 298 (2019), p. 76-81. -
További szerzők:Soltész Beáta (1987-) (molekuláris biológus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Márton Éva (1992-) (biológus) Szilágyi Melinda (1984-) (biológus) Penyige András (1954-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM078797
035-os BibID:(PMID)30904593 (WoS)000464978100008 (Scopus)85063796275
Első szerző:Lukács János (szülész-nőgyógyász, genetikus)
Cím:Identification of miR-146a and miR-196a-2 single nucleotide polymorphisms at patients with high-grade serous ovarian cancer / János Lukács, Beáta Soltész, András Penyige, Bálint Nagy, Róbert Póka
Dátum:2019
ISSN:0168-1656
Megjegyzések:MicroRNAs play an essential role in the regulation of gene expression and tumor development. Single nucleotide polymorphism (SNP) can be observed in miRNAs and could influence gene expression. We aimed to identify miR-146a rs2910164 and miR-196a-2 rs11614913 polymorphisms in ovarian cancer patients and controls. 75 patients and 75 controls were involved. DNA was isolated from blood samples. MiR-146a rs2910164 and miR-196a-2 rs11614913 were determined by LightSnip kit. We used melting curve analysis for allele classification. Network analysis was made to find common target genes. We detected 72.67% G allele frequency of miR-146a rs2910164 in controls and 82.00% in patients group (p?=?0,053). GG, GC and CC genotypes occurred with 53.33%, 38.67% and 8.00% among controls, with 65.33%, 33.33% and 1.33% among patients, (p?=?0.0917). Allele C of miR-196a-2 rs11614913 occurred in 59.33% of controls and in 67.33% of patients (p?=?0.15). CC, CT and TT genotypes occurred with 37.33%, 44.00%, and 18.67% frequency in controls, with 46.67%; 41.33% and 12.00% in patients (p?=?0.3815). Network analysis found ATG9A, LBR, MBD4 and RUFY2 genes to be targets for both miRNAs. SNPs of miR-146a and miR-196a-2 showed no significant differences between patients and controls. More investigations are required to clarify the exact role of these SNPs in ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Ovarian cancer
SNP
miR-146a
miR-196a-2
miRNA
Megjelenés:Journal Of Biotechnology. - 297 (2019), p. 54-57. -
További szerzők:Soltész Beáta (1987-) (molekuláris biológus) Penyige András (1954-) (molekuláris genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM078164
035-os BibID:(PMID)30953675 (WoS)000464978100009 (Scopus)85063866299
Első szerző:Márton Éva (biológus)
Cím:Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer / Éva Márton, János Lukács, András Penyige, Eszter Janka, Lídia Hegedüs, Beáta Soltész, Gábor Méhes, Róbert Póka, Bálint Nagy, Melinda Szilágyi
Dátum:2019
ISSN:0168-1656
Megjegyzések:Ovarian cancer is the fifth most common cause of cancer death among women that is mostly due to the difficulty of early diagnosis. Circulating miRNAs proved to be reliable biomarkers in various cancers. We screened 9 miRNAs, which are involved in epithelial-mesenchymal transition, in the plasma samples of patients with malignant (n=28) or non-malignant (n=12) ovarian tumors and disease-free healthy volunteers (n=60) by qRT-PCR. The expression levels of miR200a, miR200b, miR200c, miR141, miR429, miR203a, miR34b (p<0.001) and miR34a (p<0.01) were significantly higher in the malignant samples than in healthy controls. MiR203a, miR141 (p<0.01), miR200a and miR429 (p<0.05) levels were also higher in malignant compared to non-malignant samples. ROC-AUC was the highest in the case of miR200c: 0.861 (95%CI=0.776-0.947). Spearman's rank correlation analysis revealed positive correlation between the plasma levels of the studied miRNAs that was the highest between miR200b and miR200c (rs = 0.774; p<0.001). Target analysis also suggested tight interaction between these miRNAs in the regulation of cancer development. The agreement of diagnostic tests based on miRNA levels and the standard CA125 or HE4 was weak according to Cohen's kappa values. We conclude that miR200 family members, miR34b and miR203a might be promising complementary biomarkers in ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
petefészekrák
miRNS
miR200
miR34
miR203
CA125
HE4
Megjelenés:Journal of Biotechnology. - 297 (2019), p. 58-65. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Penyige András (1954-) (molekuláris genetikus) Janka Eszter Anna (1989-) (bőrgyógyász, népegészségügyi szakember) Hegedüs Lídia Soltész Beáta (1987-) (molekuláris biológus) Méhes Gábor (1966-) (patológus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM078708
035-os BibID:(PMID)31055145 (WoS)000471093600002 (Scopus)85065709699
Első szerző:Orosz László (szülész-nőgyógyász)
Cím:Screening for preeclampsia in the first trimester of pregnancy in routine clinical practice in Hungary / Laszlo Orosz, Gergo Orosz, Lajos Veress, Diana Dosa, Laszlo id. Orosz, Ibolya Arany, Antal Fabian, Laszlo Medve, Karoly Pap, Zsolt Karanyi, Zoltan Toth, Robert Poka, Nandor Gabor Than, Olga Torok
Dátum:2019
ISSN:0168-1656
Megjegyzések:We aimed to evaluate the contribution of different factors in the Fetal Medicine Foundation algorithms for preeclampsia (PE) risk calculation during first-trimester screening in Hungary. We selected subjects for the nested case-control study from a prospective cohort of 2,545 low-risk pregnancies. Eighty-two patients with PE and 82 gestational age-matched controls were included. Individual PE risk was calculated using two risk-assessing softwares. Using Astraia 2.3.1, considering maternal characteristics and biophysical parameters only, detection rates (DR) were 63.6% for early-PE and 67.6% for late-PE. When we added placenta associated plasma protein A (PAPP-A) to the risk calculation, DRs decreased to 54.5% and 64.8% respectively. Using Astraia 2.8.2 with maternal characteristics and biophysical parameters resulted in the DRs of 63.6% (early-PE) and 56.3% (late-PE). If we added PAPP-A to the risk calculation, DRs improved to 72.7% and 54.9%. The addition of placental growth factor (PlGF) did not increase detection rates in either calculation. In conclusion, using maternal characteristics, biophysical parameters, and PAPP-A, an acceptable screening efficacy could be achieved for early-PE during first-trimester screening. Since PlGF did not improve efficacy in our study, we suggest setting new standard curves for PlGF in Eastern European pregnant women, and the evaluation of novel biochemical markers.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Blood pressure
First trimester
Placental growth factor
Preeclampsia
Screening
Uterine artery Doppler
Megjelenés:Journal Of Biotechnology. - 300 (2019), p. 11-19. -
További szerzők:Orosz Gergő Balázs (1985-) (szülész-nőgyógyász) Veress Lajos (1950-) (vegyész) Dósa Diána id. Orosz László Arany Ibolya Fábián Antal Medve László Pap Károly Karányi Zsolt (1961-) (biostatisztikus, bioinformatikus) Tóth Zoltán (1948-) (szülész-nőgyógyász, humángenetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Than Nándor Gábor (szülész-nőgyógyász) Török Olga (1956-) (szülész-nőgyógyász, humángenetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM078519
035-os BibID:(PMID)30959137 (WoS)000466942100004 (Scopus)85064114120
Első szerző:Soltész Beáta (molekuláris biológus)
Cím:Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients / Beáta Soltész, János Lukács, Edina Szilágyi, Éva Márton, Melinda Szilágyi-Bónizs, András Penyige, Róbert Póka, Bálint Nagy
Dátum:2019
ISSN:0168-1656
Megjegyzések:CD24 is a small molecular weight cell-surface protein and an independent marker for poor prognosis in the different type of cancers. We aimed to determine the expression of CD24 in plasma, exosomes and ovarian tissue samples of serous ovarian cancer patients. We collected tissue and blood samples from 21 cases of serous ovarian cancer and eight healthy controls. We used silica adsorption method for isolation of RNA. The cDNA was synthesized using quantitative real-time PCR. We used beta-globin as a housekeeping gene for the normalization of the data. Protein-protein and miRNA networking were analyzed. There was a significant difference in the expression of CD24 in ovarian tissue between controls and patients (0.16?±?0.32 vs. 44.97?±?68.06; p?<?0.01), while CD24 did not show expression in each plasma and exosome samples. There was a correlation in the expression of CD24 and FIGO grading between controls and patients. CD24 expression was detected in exosomes in 38.1% of patients, mainly with FIGO III, and in their plasma in 9.5% of cases. Our network analysis shows LYN, SELP, FGR, and NPM1 proteins are interacting with CD24. Our study demonstrates higher expression of CD24 in ovarian cancer patients' tissue samples, and there is an association with FIGO classification. However, CD24 showed expression only in some cell-free plasma and exosome samples.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
CD24
Cell-free nucleic acids
Exosomes
Ovarian cancer
Plasma
Megjelenés:Journal of Biotechnology. - 298 (2019), p. 16-20. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Szilágyi Edina (1993-) (laboratóriumi analitikus) Márton Éva (1992-) (biológus) Szilágyi Melinda (1984-) (biológus) Penyige András (1954-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.